Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin feasibility pilot in children with dystonic cerebral palsy
ACTRN12616000366459Phase 3Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gabapentin in dystonic cerebral palsy, sponsored by Murdoch Children's Research Institute. Primary endpoints: Composite feasibility outcome at 12 weeks and Complications and side effects at 12 weeks. Started Nov 2016; status: completed.
02
Drugs
gabapentin
03
Conditions
dystonic cerebral palsy
Beyond the preview
Go deeper on ACTRN12616000366459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000366459.